Literature DB >> 23752116

Ruxolitinib withdrawal syndrome leading to tumor lysis.

Tong Dai1, Ellen W Friedman, Stefan K Barta.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23752116     DOI： 10.1200/JCO.2012.47.6473

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  11 in total

1.  Rapid disease progression following discontinuation of ibrutinib in patients with chronic lymphocytic leukemia treated in routine clinical practice.

Authors:  Paul J Hampel; Wei Ding; Timothy G Call; Kari G Rabe; Saad S Kenderian; Thomas E Witzig; Eli Muchtar; Jose F Leis; Asher A Chanan-Khan; Amber B Koehler; Amie L Fonder; Susan M Schwager; Susan L Slager; Tait D Shanafelt; Neil E Kay; Sameer A Parikh
Journal:  Leuk Lymphoma       Date:  2019-04-24

2.  Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Myelofibrosis with Prior Exposure to Janus Kinase 1/2 Inhibitors.

Authors:  Mohamed Shanavas; Uday Popat; Laura C Michaelis; Veena Fauble; Donal McLornan; Rebecca Klisovic; John Mascarenhas; Roni Tamari; Murat O Arcasoy; James Davies; Usama Gergis; Oluchi C Ukaegbu; Rammurti T Kamble; John M Storring; Navneet S Majhail; Rizwan Romee; Srdan Verstovsek; Antonio Pagliuca; Sumithira Vasu; Brenda Ernst; Eshetu G Atenafu; Ahmad Hanif; Richard Champlin; Paremeswaran Hari; Vikas Gupta
Journal:  Biol Blood Marrow Transplant       Date:  2015-10-19       Impact factor: 5.742

3.  Ruxolitinib before allogeneic hematopoietic transplantation in patients with myelofibrosis on behalf SFGM-TC and FIM groups.

Authors:  Gérard Socié; Jean-Jacques Kiladjian; Marie Robin; Raphael Porcher; Corentin Orvain; Jacques-Olivier Bay; Fiorenza Barraco; Anne Huynh; Amandine Charbonnier; Edouard Forcade; Sylvain Chantepie; Claude Bulabois; Ibrahim Yakoub-Agha; Marie Detrait; David Michonneau; Pascal Turlure; Nicole Raus; Françoise Boyer; Felipe Suarez; Laure Vincent; Stéphanie N Guyen; Jérôme Cornillon; Alban Villate; Brigitte Dupriez; Bruno Cassinat; Valérie Rolland; Marie Hélène Schlageter
Journal:  Bone Marrow Transplant       Date:  2021-03-25       Impact factor: 5.174

Review 4.  Definition and management of ruxolitinib treatment failure in myelofibrosis.

Authors:  A Pardanani; A Tefferi
Journal:  Blood Cancer J       Date:  2014-12-12       Impact factor: 11.037

5.  Tumor Lysis Syndrome after the Administration of Ruxolitinib in a Patient with Post-polycythemia Vera Myelofibrosis.

Authors:  Megumi Koshiishi; Yuki Sueki; Ichiro Kawashima; Kei Nakajima; Toru Mitsumori; Keita Kirito
Journal:  Intern Med       Date:  2017-08-10       Impact factor: 1.271

6.  Accumulation of JAK activation loop phosphorylation is linked to type I JAK inhibitor withdrawal syndrome in myelofibrosis.

Authors:  Denis Tvorogov; Daniel Thomas; Nicholas P D Liau; Mara Dottore; Emma F Barry; Maya Lathi; Winnie L Kan; Timothy R Hercus; Frank Stomski; Timothy P Hughes; Vinay Tergaonkar; Michael W Parker; David M Ross; Ravindra Majeti; Jeffrey J Babon; Angel F Lopez
Journal:  Sci Adv       Date:  2018-11-28       Impact factor: 14.136

7.  Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis.

Authors:  Francesca Palandri; Giuseppe Alberto Palumbo; Elena Maria Elli; Nicola Polverelli; Giulia Benevolo; Bruno Martino; Elisabetta Abruzzese; Mario Tiribelli; Alessia Tieghi; Roberto Latagliata; Francesco Cavazzini; Micaela Bergamaschi; Gianni Binotto; Monica Crugnola; Alessandro Isidori; Giovanni Caocci; Florian Heidel; Novella Pugliese; Costanza Bosi; Daniela Bartoletti; Giuseppe Auteri; Daniele Cattaneo; Luigi Scaffidi; Malgorzata Monica Trawinska; Rossella Stella; Fiorella Ciantia; Fabrizio Pane; Antonio Cuneo; Mauro Krampera; Gianpietro Semenzato; Roberto Massimo Lemoli; Alessandra Iurlo; Nicola Vianelli; Michele Cavo; Massimo Breccia; Massimiliano Bonifacio
Journal:  Blood Cancer J       Date:  2021-01-07       Impact factor: 11.037

8.  Acute respiratory distress syndrome; A rare complication caused by usage of ruxolitinib.

Authors:  Bugra Kerget; Omer Araz; Elif Yilmazel Ucar; Metin Akgun; Leyla Sağlam
Journal:  Respir Med Case Rep       Date:  2017-09-18

Review 9.  Management of myelofibrosis after ruxolitinib failure.

Authors:  Claire N Harrison; Nicolaas Schaap; Ruben A Mesa
Journal:  Ann Hematol       Date:  2020-03-20       Impact factor: 3.673

10.  Acute respiratory distress syndrome in a patient with primary myelofibrosis after ruxolitinib treatment discontinuation.

Authors:  Yan Beauverd; Kaveh Samii
Journal:  Int J Hematol       Date:  2014-07-18       Impact factor: 2.490
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.